Lukas Löfling er epidemiolog og forsker i Kreftregisteret. Han studerer assosiasjoner mellom ikke-kreftlegemiddel og risiko for kreft og prognosen etter kreftdiagnose
Utdanning:
2015 - Master i farmasi, Uppsala Universitet
2020 - PhD i medisinsk vitenskap (kreftepidemiologi), Karolinska Institutet (2020), ”Lung cancer in Sweden – Incidence, diagnosis and survival”
Assosiasjon mellom acetylsalisylsyre, metformin og beta-blokkere med forekomst og overlevelse av kreft.
Löfling LL, Støer NC, Andreassen BK, Ursin G, Botteri E. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Res. 2023 Aug 30;25(1):101. doi: 10.1186/s13058-023-01697-2. PMID: 37649039; PMCID: PMC10466817.
Sanjinez C, Botteri E, Støer NC, Lukas Löfling L. Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study. Lung Cancer. 2023 May;179:107187. doi: 10.1016/j.lungcan.2023.107187. Epub 2023 Apr 5. PMID: 37060880.
Chang A, Botteri E, Gillis RD, Löfling L, Le CP, Ziegler AI, Chung NC, Rowe MC, Fabb SA, Hartley BJ, Nowell CJ, Kurozumi S, Gandini S, Munzone E, Montagna E, Eikelis N, Phillips SE, Honda C, Masuda K, Katayama A, Oyama T, Cole SW, Lambert GW, Walker AK, Sloan EK. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci Transl Med. 2023 Apr 26;15(693):eadf1147. doi: 10.1126/scitranslmed.adf1147. Epub 2023 Apr 26. PMID: 37099632.
Løfling L, Støer NC, Nafisi S, Ursin G, Hofvind S, Botteri E. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. Eur J Epidemiol. 2023 Apr;38(4):413-426. doi: 10.1007/s10654-023-00976-8. Epub 2023 Mar 6. PMID: 36877278; PMCID: PMC10082109.
Løfling LL, Støer NC, Sloan EK, Chang A, Gandini S, Ursin G, Botteri E. β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer. 2022 Oct;127(6):1086-1096. doi: 10.1038/s41416-022-01891-7. Epub 2022 Jun 20. PMID: 35725814; PMCID: PMC9470740.
Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Temporal trends in lung cancer survival: a population-based study. Acta Oncol. 2022 May;61(5):625-631. doi: 10.1080/0284186X.2021.2013529. Epub 2021 Dec 10. PMID: 34889167.
Löfling L, Karimi A, Sandin F, Bahmanyar S, Kieler H, Lambe M, Lamberg K, Wagenius G. Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study. Acta Oncol. 2019 Nov;58(11):1618-1627. doi: 10.1080/0284186X.2019.1638521. Epub 2019 Aug 2. PMID: 31373239.
